COAG
Hemab Therapeutics Holdings, Inc.
$24.98
-7.28%
$1.2B
No data for this timeframe.
Vol
Market Cap$1.2B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (89%)
Insider Activity9B / 0S
Insider Net $$49.1M
SEC Reports10
Press Releases1
Recent Activity
May 21, 2026
SEC
Hemab Therapeutics reported a Q1 2026 net loss of $22.7M ($23.98/share), widening from a $15.3M loss ($16.18/share) in Q
PRESS-RELEASE — Impact 5/10
May 21, 2026
earnings
Hemab Therapeutics Reports First Quarter 2026 Financial Results
<p align="center"><em>Completed Initial Public Offering in May 2026, raising gross proceeds of $346.
May 20, 2026
Insider
RA CAPITAL MANAGEMENT, L.P. bought 996 shares
10%+ Owner @ $24.94 ($24.8K)
May 19, 2026
Insider
RA CAPITAL MANAGEMENT, L.P. bought 3,802 shares
10%+ Owner @ $24.97 ($94.9K)
May 12, 2026
Insider
RA CAPITAL MANAGEMENT, L.P. bought 6,387 shares
10%+ Owner @ $24.90 ($159.0K)
May 4, 2026
SEC
Hemab Therapeutics completed its IPO of 19,262,500 shares at $18.00/share, raising $346.7M in gross proceeds. Concurrent
8-K — Impact 4/10
Apr 30, 2026
Press
Hemab Therapeutics priced its IPO at $18.00 per share, offering 16.75M shares for gross proceeds of ~$301.5M, with an un
Impact 5/10
Apr 30, 2026
SEC
Novo Holdings A/S filed a Form 3 initial statement of beneficial ownership, disclosing holdings in Hemab Therapeutics (C
3 — Impact 3/10
Price Targets
$41.75
+67.1% upside
Strong Buy
Current $24.98
Low $36.00
Median $40.50
High $50.00
4 analysts
$36.00
$50.00
Analyst Ratings
3Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 26, 2026 | Wedbush | INITIATE | Outperform |
| May 26, 2026 | Jefferies | INITIATE | Buy |
| May 26, 2026 | Evercore ISI Group | INITIATE | Outperform |
| May 26, 2026 | Goldman Sachs | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.88 | $-1.23 — $-0.53 | 2 | |
| Next Q | $-0.46 | $-0.52 — $-0.40 | 2 | |
| Current FY | $-3.04 | $-3.59 — $-2.48 | 2 | |
| Next FY | $-2.33 | $-2.47 — $-2.18 | 23% YoY | 2 |
Latest Reports
NEUTRAL
PRESS-RELEASE
5/10
Hemab Therapeutics reported a Q1 2026 net loss of $22.7M ($23.98/share), widening from a $15.3M loss ($16.18/share) in Q
May 21, 2026
NEUTRAL
8-K
4/10
Hemab Therapeutics completed its IPO of 19,262,500 shares at $18.00/share, raising $346.7M in gross proceeds. Concurrent
May 4, 2026
NEUTRAL
Press
5/10
Hemab Therapeutics priced its IPO at $18.00 per share, offering 16.75M shares for gross proceeds of ~$301.5M, with an un
Apr 30, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 20, 2026 | RA CAPITAL | BUY | $24.8K |
| May 19, 2026 | RA CAPITAL | BUY | $94.9K |
| May 12, 2026 | RA CAPITAL | BUY | $159.0K |
| May 11, 2026 | RA CAPITAL | BUY | $346.2K |
| May 8, 2026 | RA CAPITAL | BUY | $37.0K |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
4 unique insiders with 22 transactions. Net insider value: $49.1M ($49.1M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | BUY | 996 | $24.94 | $24.8K |
| May 19, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | BUY | 3,802 | $24.97 | $94.9K |
| May 12, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | BUY | 6,387 | $24.90 | $159.0K |
| May 11, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | BUY | 14,149 | $24.47 | $346.2K |
| May 8, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | BUY | 1,483 | $24.98 | $37.0K |
| May 7, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | BUY | 7,921 | $24.34 | $192.8K |
| May 6, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 14,611 | $23.77 | $347.3K |
| May 5, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 87,143 | $24.59 | $2.1M |
| May 4, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | CONVERT | 56,972 | — | — |
| May 4, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | CONVERT | 42,341 | — | — |
| May 4, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | CONVERT | 64,680 | — | — |
| May 4, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 2,541,250 | $18.00 | $45.7M |
| May 4, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | CONVERT | 3,607,846 | — | — |
| May 4, 2026 | Novo Holdings A/S | 10%+ Owner | CONVERT | 32,695 | — | — |
| May 4, 2026 | Novo Holdings A/S | 10%+ Owner | CONVERT | 62,121 | — | — |
| May 4, 2026 | Novo Holdings A/S | 10%+ Owner | CONVERT | 71,866 | — | — |
| May 4, 2026 | Novo Holdings A/S | 10%+ Owner | CONVERT | 23,343 | — | — |
| May 4, 2026 | Novo Holdings A/S | 10%+ Owner | CONVERT | 4,180,550 | — | — |
| Apr 30, 2026 | Behrndt-Eriksen Mads Nikolaj | See Remarks | AWARD | 49,016 | — | — |
| Apr 30, 2026 | Madigan Catherine | Chief Medical Officer | AWARD | 49,016 | — | — |
| Jan 29, 2026 | Behrndt-Eriksen Mads Nikolaj | See Remarks | AWARD | 195,206 | — | — |
| Jan 29, 2026 | Madigan Catherine | Chief Medical Officer | AWARD | 145,134 | — | — |
10 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 9 neutral. Avg impact: 3.1/10.
NEUTRAL
PRESS-RELEASE
5/10
Hemab Therapeutics reported a Q1 2026 net loss of $22.7M ($23.98/share), widening from a $15.3M loss
May 21, 2026
NEUTRAL
8-K
4/10
Hemab Therapeutics completed its IPO of 19,262,500 shares at $18.00/share, raising $346.7M in gross
May 4, 2026
NEUTRAL
3
3/10
Novo Holdings A/S filed a Form 3 initial statement of beneficial ownership, disclosing holdings in H
Apr 30, 2026
NEUTRAL
3
3/10
RA Capital Management and affiliated entities filed Form 3 initial statements of beneficial ownershi
Apr 30, 2026
NEUTRAL
3
2/10
John Michael Maraganore filed an initial statement of beneficial ownership (Form 3) with the SEC, di
Apr 30, 2026
NEUTRAL
3
2/10
Linda Catharina Bain filed a Form 3 initial statement of beneficial ownership with the SEC, disclosi
Apr 30, 2026
NEUTRAL
3
2/10
Laura Tadvalkar filed a Form 3 initial statement of beneficial ownership with Hemab Therapeutics Hol
Apr 30, 2026
NEUTRAL
3
2/10
Two insiders at Hemab Therapeutics (COAG) filed initial statements of beneficial ownership (Form 3)
Apr 30, 2026
NEUTRAL
3
2/10
Benny Sorensen, the President and CEO of Hemab Therapeutics, filed an initial Form 3 disclosing bene
Apr 30, 2026
MIXED
S-1/A
6/10
Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotech company developing therapies fo
Apr 27, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 3 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$41.75 mean target
+67.1% upside
Strong Buy (1.00)
$36.00 Low
$50.00 High
| Metric | Value |
|---|---|
| Current Price | $24.98 |
| Target Low | $36.00 |
| Target Mean | $41.75 |
| Target Median | $40.50 |
| Target High | $50.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.88 | $-1.23 | $-0.53 | — | — | — | $0.0B | — | 2 |
| Next Q 2026-09-30 |
$-0.46 | $-0.52 | $-0.40 | — | — | — | $0.0B | — | 2 |
| Current FY 2026-12-31 |
$-3.04 | $-3.59 | $-2.48 | — | — | — | $0.0B | — | 2 |
| Next FY 2027-12-31 |
$-2.33 | $-2.47 | $-2.18 | 23.4% | — | — | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.880 | |
| 7d ago | $0.000 | -0.880 |
| 30d ago | $0.000 | -0.880 |
| 60d ago | $0.000 | -0.880 |
| 90d ago | $0.000 | -0.880 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 4 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 26, 2026 | Wedbush | INITIATE | — | Outperform |
| May 26, 2026 | Jefferies | INITIATE | — | Buy |
| May 26, 2026 | Evercore ISI Group | INITIATE | — | Outperform |
| May 26, 2026 | Goldman Sachs | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 21, 2026
earnings
Hemab Therapeutics Reports First Quarter 2026 Financial Results
<p align="center"><em>Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq</em></p>
May 5, 2026
short_interest
FTD: COAG — 28,113 shares ($0.7M) failed to deliver
Settlement: 20260505, Price: $25.34, FTD Value: $712,383.42, HEMAB THERAPEUTICS HLDGS INC C
May 4, 2026
offering
Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
<p align="left">CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clin
May 4, 2026
short_interest
FTD: COAG — 73,264 shares ($2.5M) failed to deliver
Settlement: 20260504, Price: $34.00, FTD Value: $2,490,976, HEMAB THERAPEUTICS HLDGS INC C
Apr 30, 2026
offering
Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering
<p align="start">CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a cl